The global transfection technologies market size reached US$ 1,172.0 million in 2023. The market is projected to reach US$ 2,275.3 million by 2032, exhibiting a growth rate (CAGR) of 7.65% during 2023-2032.
Transfection technology refers to the process of artificially introducing nucleic acid, such as Deoxyribonucleic Acid (DNA), Ribonucleic Acid (RNA) and oligonucleotides, into the cells. It is introduced using various physical, chemical and biological methods, which can assist in modifying certain properties of the cell. It involves various methods, including cotransfection, electroporation, cationic lipid transfection and in-vivo transfection. This process is commonly used for various genomic studies that include gene expression, screening, RNA interference and Vivo research, along with the bioproduction of viruses and proteins.
The increasing prevalence of cancer and various chronic lifestyle diseases is one of the key factors driving the growth of the market. Furthermore, widespread adoption of reagent-based methods is also providing a boost to the market growth. In comparison to the traditionally used techniques, reagent-based transfection is less complicated to administer and more cost-effective. In line with this, instrument-based methods, such as biolistic technology, microinjection and laserfection, are also gaining immense traction across the globe. Various technological advancements in cell research and therapeutic discovery are acting as another major growth-inducing factor. In line with this, research in gene transfer is majorly performed under in-vivo conditions for the development of novel therapeutic drugs and various other applications. Other factors, including increasing investments by both government and private organizations to develop large scale transfection facilities, along with extensive research and development (R&D) activities in the field of protein therapeutics, are projected to drive the market further.
2. What is the expected growth rate of the global transfection technologies market during 2024-2032?
3. What are the key factors driving the global transfection technologies market?
4. What has been the impact of COVID-19 on the global transfection technologies market?
5. What is the breakup of the global transfection technologies market based on the product type?
6. What is the breakup of the global transfection technologies market based on the application?
7. What is the breakup of the global transfection technologies market based on the transfection method?
8. What is the breakup of the global transfection technologies market based on the technology?
9. What are the key regions in the global transfection technologies market?
10. Who are the key players/companies in the global transfection technologies market?
Transfection technology refers to the process of artificially introducing nucleic acid, such as Deoxyribonucleic Acid (DNA), Ribonucleic Acid (RNA) and oligonucleotides, into the cells. It is introduced using various physical, chemical and biological methods, which can assist in modifying certain properties of the cell. It involves various methods, including cotransfection, electroporation, cationic lipid transfection and in-vivo transfection. This process is commonly used for various genomic studies that include gene expression, screening, RNA interference and Vivo research, along with the bioproduction of viruses and proteins.
The increasing prevalence of cancer and various chronic lifestyle diseases is one of the key factors driving the growth of the market. Furthermore, widespread adoption of reagent-based methods is also providing a boost to the market growth. In comparison to the traditionally used techniques, reagent-based transfection is less complicated to administer and more cost-effective. In line with this, instrument-based methods, such as biolistic technology, microinjection and laserfection, are also gaining immense traction across the globe. Various technological advancements in cell research and therapeutic discovery are acting as another major growth-inducing factor. In line with this, research in gene transfer is majorly performed under in-vivo conditions for the development of novel therapeutic drugs and various other applications. Other factors, including increasing investments by both government and private organizations to develop large scale transfection facilities, along with extensive research and development (R&D) activities in the field of protein therapeutics, are projected to drive the market further.
Key Market Segmentation:
The report provides an analysis of the key trends in each sub-segment of the global transfection technologies market report, along with forecasts at the global, regional and country level from 2023-2032. The report has categorized the market based on product type, application, transfection method, technology and end-user.Breakup by Product Type:
- Reagent
- Instrument
- Others
Breakup by Application:
- Therapeutic Delivery
- Bio-Medical Research
- Protein Production
- Others
Breakup by Transfection Method:
- Lipofection
- Eletroporation
- Nucleofection
- Cotransfection
- Cationic Lipid Transfection
- In-Vivo Transfection
- Others
Breakup by Technology:
- Physical Transfection
- Biochemical Based Transfection
- Viral-Vector Based Transfection
Breakup by End-User:
- Research Centers and Academic Institutes
- Hospitals and Clinics
- Pharmaceutical and Biotechnology Companies
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., Bio-RAD Laboratories Inc., Lonza Group AG, Maxcyte Inc., Mirus Bio LLC, Polyplus Transfection, Promega Corporation, Roche Holding AG, Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., etc.Key Questions Answered in This Report
1. What was the size of the global transfection technologies market in 2023?2. What is the expected growth rate of the global transfection technologies market during 2024-2032?
3. What are the key factors driving the global transfection technologies market?
4. What has been the impact of COVID-19 on the global transfection technologies market?
5. What is the breakup of the global transfection technologies market based on the product type?
6. What is the breakup of the global transfection technologies market based on the application?
7. What is the breakup of the global transfection technologies market based on the transfection method?
8. What is the breakup of the global transfection technologies market based on the technology?
9. What are the key regions in the global transfection technologies market?
10. Who are the key players/companies in the global transfection technologies market?
Table of Contents
1 Preface3 Executive Summary13 Value Chain Analysis
2 Scope and Methodology
4 Introduction
5 Global Transfection Technologies Market
6 Market Breakup by Product Type
7 Market Breakup by Application
8 Market Breakup by Transfection Method
9 Market Breakup by Technology
10 Market Breakup by End-User
11 Market Breakup by Region
12 SWOT Analysis
14 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Agilent Technologies Inc.
- Bio-RAD Laboratories Inc.
- Lonza Group AG
- Maxcyte Inc.
- Mirus Bio LLC
- Polyplus Transfection
- Promega Corporation
- Roche Holding AG
- Sigma-Aldrich Corporation and Thermo Fisher Scientific Inc.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 140 |
Published | January 2024 |
Forecast Period | 2023 - 2032 |
Estimated Market Value ( USD | $ 1.17 Billion |
Forecasted Market Value ( USD | $ 2.27 Billion |
Compound Annual Growth Rate | 7.6% |
Regions Covered | Global |
No. of Companies Mentioned | 9 |